Breaking News, Collaborations & Alliances

WuXi Biologics, ABL Bio Enter Development Deal

For up to 8 antibody therapeutics including ABL Bio’s biologics pipelines & collaboration programs between ABL Bio and I-Mab

WuXi Biologics and ABL Bio Corporation have entered into an exclusive development and clinical manufacturing partnership for up to 8 antibody therapeutics including ABL Bio’s biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma. The agreement showcases the biologics pipeline of ABL Bio and technical expertise and capabilities of WuXi Biologics in developing bispecific programs. “We are very pleased to enter into this partnership with WuXi Biologics. The partnersh...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters